Evaluating Different Low-level Laser Therapies to Treat Neck Pain in Air Force Pilots and Flight Crew
NCT ID: NCT03945240
Last Updated: 2025-12-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
80 participants
INTERVENTIONAL
2020-10-01
2025-12-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1 (Pinnacle, lower dosimetry parameters)
Utilize the Pinnacle Series Laser by Aspen Laser Systems to apply LLLT
Group 1 -- using Pinnacle Series Laser Device
Utilizing the Pinnacle Series Laser by Aspen Laser Systems, investigators will apply 635-780nm, 10 mW cw, \~ 5-105 J/cm2 at the following time and mW intervals. The beam will be applied at 12 application patterns equidistant and parallel to each other. Each application point will be treated for the timeframes referenced below:
* Subgroup 1: 10 minutes at 5 mW
* Subgroup 2: 10 minutes at 15 mW
* Subgroup 3: 10 minutes at 32 mW
* Subgroup 4: 15 minutes at 5 mW
* Subgroup 5: 15 minutes at 15 mW
* Subgroup 6: 15 minutes at 32 mW
Group 2 (Pinnacle, higher dosimetry parameters)
Utilize the Pinnacle Series Laser by Aspen Laser Systems to apply LLLT
Group 2 -- using Pinnacle Series Laser Device
Utilizing the Pinnacle Series Laser by Aspen Laser Systems, we will apply 830nm, 30- 50mW cw, \~ 1-20 J/cm2 at the following time and mW intervals. The beam will be applied at 12 application patterns equidistant and parallel to each other. Each application point will be treated for the timeframes referenced below:
* Subgroup 1: 10 minutes at 5 mW
* Subgroup 2: 10 minutes at 15 mW
* Subgroup 3: 10 minutes at 32 mW
* Subgroup 4: 15 minutes at 5 mW
* Subgroup 5: 15 minutes at 15 mW
* Subgroup 6: 15 minutes at 32 mW
Group 3 (Phoenix)
Utilizing the Phoenix Thera-Lase by Phoenix Thera-Lase Systems, we will apply LLT.
Group 3 -- using Phoenix Thera-Lase Device
Utilizing the Phoenix Thera-Lase by Phoenix Thera-Lase Systems, we will apply 904nm, 40mW (pulsed) @10000Hz, \~ 4-18 J/cm2 at the following time and mW intervals. The beam will be applied at 12 application patterns equidistant and parallel to each other. Each application point will be treated for the timeframes referenced below:
* Subgroup 1: 10 minutes at 5 mW
* Subgroup 2: 10 minutes at 15 mW
* Subgroup 3: 10 minutes at 32 mW
* Subgroup 4: 15 minutes at 5 mW
* Subgroup 5: 15 minutes at 15 mW
* Subgroup 6: 15 minutes at 32 mW
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Group 1 -- using Pinnacle Series Laser Device
Utilizing the Pinnacle Series Laser by Aspen Laser Systems, investigators will apply 635-780nm, 10 mW cw, \~ 5-105 J/cm2 at the following time and mW intervals. The beam will be applied at 12 application patterns equidistant and parallel to each other. Each application point will be treated for the timeframes referenced below:
* Subgroup 1: 10 minutes at 5 mW
* Subgroup 2: 10 minutes at 15 mW
* Subgroup 3: 10 minutes at 32 mW
* Subgroup 4: 15 minutes at 5 mW
* Subgroup 5: 15 minutes at 15 mW
* Subgroup 6: 15 minutes at 32 mW
Group 2 -- using Pinnacle Series Laser Device
Utilizing the Pinnacle Series Laser by Aspen Laser Systems, we will apply 830nm, 30- 50mW cw, \~ 1-20 J/cm2 at the following time and mW intervals. The beam will be applied at 12 application patterns equidistant and parallel to each other. Each application point will be treated for the timeframes referenced below:
* Subgroup 1: 10 minutes at 5 mW
* Subgroup 2: 10 minutes at 15 mW
* Subgroup 3: 10 minutes at 32 mW
* Subgroup 4: 15 minutes at 5 mW
* Subgroup 5: 15 minutes at 15 mW
* Subgroup 6: 15 minutes at 32 mW
Group 3 -- using Phoenix Thera-Lase Device
Utilizing the Phoenix Thera-Lase by Phoenix Thera-Lase Systems, we will apply 904nm, 40mW (pulsed) @10000Hz, \~ 4-18 J/cm2 at the following time and mW intervals. The beam will be applied at 12 application patterns equidistant and parallel to each other. Each application point will be treated for the timeframes referenced below:
* Subgroup 1: 10 minutes at 5 mW
* Subgroup 2: 10 minutes at 15 mW
* Subgroup 3: 10 minutes at 32 mW
* Subgroup 4: 15 minutes at 5 mW
* Subgroup 5: 15 minutes at 15 mW
* Subgroup 6: 15 minutes at 32 mW
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* maintain operational flight status at enrollment or within the last 6 months
* History of neck pain for a period of more than two months
* Score on the Neck Disability Index ranging from 15-24
* No physiotherapy or local injection in 3 months before starting the study
Exclusion Criteria
* major surgery or trauma in the previous 3 months
* unstable cervical spine
* cervical radiculopathy
* rheumatoid arthritis
* open wound over neck
* pace-maker or defibrillator implantation
* overt neuropathic pain or radiation pain
* inability to express pain or quality of life.
* history of neurological disorders
* medical diagnosis of fibromyalgia; systemic disease
18 Years
62 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Paul Crawford
FED
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Paul Crawford
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Paul F Crawford, MD
Role: PRINCIPAL_INVESTIGATOR
US Air Force
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mike O'Callaghan Military Medical Center
Las Vegas, Nevada, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ceccherelli F, Altafini L, Lo Castro G, Avila A, Ambrosio F, Giron GP. Diode laser in cervical myofascial pain: a double-blind study versus placebo. Clin J Pain. 1989 Dec;5(4):301-4. doi: 10.1097/00002508-198912000-00005.
Ozdemir F, Birtane M, Kokino S. The clinical efficacy of low-power laser therapy on pain and function in cervical osteoarthritis. Clin Rheumatol. 2001;20(3):181-4. doi: 10.1007/s100670170061.
Hamalainen O, Heinijoki H, Vanharanta H. Neck training and +Gz-related neck pain: a preliminary study. Mil Med. 1998 Oct;163(10):707-8.
Harrison MF, Neary JP, Albert WJ, Kuruganti U, Croll JC, Chancey VC, Bumgardner BA. Measuring neuromuscular fatigue in cervical spinal musculature of military helicopter aircrew. Mil Med. 2009 Nov;174(11):1183-9. doi: 10.7205/milmed-d-00-7409.
Salmon DM, Harrison MF, Neary JP. Neck pain in military helicopter aircrew and the role of exercise therapy. Aviat Space Environ Med. 2011 Oct;82(10):978-87. doi: 10.3357/asem.2841.2011.
(2018) International Association for the Study of Pain : Neck pain.
Benyamin R, Trescot AM, Datta S, Buenaventura R, Adlaka R, Sehgal N, Glaser SE, Vallejo R. Opioid complications and side effects. Pain Physician. 2008 Mar;11(2 Suppl):S105-20.
Attal N, Lanteri-Minet M, Laurent B, Fermanian J, Bouhassira D. The specific disease burden of neuropathic pain: results of a French nationwide survey. Pain. 2011 Dec;152(12):2836-2843. doi: 10.1016/j.pain.2011.09.014. Epub 2011 Oct 20.
Torrance N, Ferguson JA, Afolabi E, Bennett MI, Serpell MG, Dunn KM, Smith BH. Neuropathic pain in the community: more under-treated than refractory? Pain. 2013 May;154(5):690-699. doi: 10.1016/j.pain.2012.12.022. Epub 2013 Jan 23.
Mester E, Ludany G, Sellyei M, Szende B, Gyenes G, Tota GJ. [Studies on the inhibiting and activating effects of laser beams]. Langenbecks Arch Chir. 1968;322:1022-7. doi: 10.1007/BF02453990. No abstract available. German.
Avci P, Gupta A, Sadasivam M, Vecchio D, Pam Z, Pam N, Hamblin MR. Low-level laser (light) therapy (LLLT) in skin: stimulating, healing, restoring. Semin Cutan Med Surg. 2013 Mar;32(1):41-52.
(2018) North American Association for Photobiomodulation Therapy.
Guarini D, Gracia B, Ramirez-Lobos V, Noguera-Pantoja A, Sole-Ventura P. Laser Biophotomodulation in Patients with Neurosensory Disturbance of the Inferior Alveolar Nerve After Sagittal Split Ramus Osteotomy: A 2-Year Follow-Up Study. Photomed Laser Surg. 2018 Jan;36(1):3-9. doi: 10.1089/pho.2017.4312. Epub 2017 Oct 12.
Chow RT, Heller GZ, Barnsley L. The effect of 300 mW, 830 nm laser on chronic neck pain: a double-blind, randomized, placebo-controlled study. Pain. 2006 Sep;124(1-2):201-10. doi: 10.1016/j.pain.2006.05.018. Epub 2006 Jun 27.
Enwemeka CS, Parker JC, Dowdy DS, Harkness EE, Sanford LE, Woodruff LD. The efficacy of low-power lasers in tissue repair and pain control: a meta-analysis study. Photomed Laser Surg. 2004 Aug;22(4):323-9. doi: 10.1089/pho.2004.22.323.
Carrasco TG, Guerisoli LD, Guerisoli DM, Mazzetto MO. Evaluation of low intensity laser therapy in myofascial pain syndrome. Cranio. 2009 Oct;27(4):243-7. doi: 10.1179/crn.2009.035.
Olavi A, Pekka R, Pertti K, Pekka P. Effects of the infrared laser therapy at treated and non-treated trigger points. Acupunct Electrother Res. 1989;14(1):9-14. doi: 10.3727/036012989816358560.
Graham N, Gross AR, Carlesso LC, Santaguida PL, Macdermid JC, Walton D, Ho E; ICON. An ICON Overview on Physical Modalities for Neck Pain and Associated Disorders. Open Orthop J. 2013 Sep 20;7:440-60. doi: 10.2174/1874325001307010440. eCollection 2013.
Konstantinovic LM, Cutovic MR, Milovanovic AN, Jovic SJ, Dragin AS, Letic MDj, Miler VM. Low-level laser therapy for acute neck pain with radiculopathy: a double-blind placebo-controlled randomized study. Pain Med. 2010 Aug;11(8):1169-78. doi: 10.1111/j.1526-4637.2010.00907.x.
Gur A, Sarac AJ, Cevik R, Altindag O, Sarac S. Efficacy of 904 nm gallium arsenide low level laser therapy in the management of chronic myofascial pain in the neck: a double-blind and randomize-controlled trial. Lasers Surg Med. 2004;35(3):229-35. doi: 10.1002/lsm.20082.
Ilbuldu E, Cakmak A, Disci R, Aydin R. Comparison of laser, dry needling, and placebo laser treatments in myofascial pain syndrome. Photomed Laser Surg. 2004 Aug;22(4):306-11. doi: 10.1089/pho.2004.22.306.
Hakguder A, Birtane M, Gurcan S, Kokino S, Turan FN. Efficacy of low level laser therapy in myofascial pain syndrome: an algometric and thermographic evaluation. Lasers Surg Med. 2003;33(5):339-43. doi: 10.1002/lsm.10241.
Woodruff LD, Bounkeo JM, Brannon WM, Dawes KS, Barham CD, Waddell DL, Enwemeka CS. The efficacy of laser therapy in wound repair: a meta-analysis of the literature. Photomed Laser Surg. 2004 Jun;22(3):241-7. doi: 10.1089/1549541041438623.
Huang YY, Chen AC, Carroll JD, Hamblin MR. Biphasic dose response in low level light therapy. Dose Response. 2009 Sep 1;7(4):358-83. doi: 10.2203/dose-response.09-027.Hamblin.
Huang YY, Sharma SK, Carroll J, Hamblin MR. Biphasic dose response in low level light therapy - an update. Dose Response. 2011;9(4):602-18. doi: 10.2203/dose-response.11-009.Hamblin. Epub 2011 Sep 2.
Huang YY, Nagata K, Tedford CE, McCarthy T, Hamblin MR. Low-level laser therapy (LLLT) reduces oxidative stress in primary cortical neurons in vitro. J Biophotonics. 2013 Oct;6(10):829-38. doi: 10.1002/jbio.201200157. Epub 2012 Dec 27.
Huang YY, Nagata K, Tedford CE, Hamblin MR. Low-level laser therapy (810 nm) protects primary cortical neurons against excitotoxicity in vitro. J Biophotonics. 2014 Aug;7(8):656-64. doi: 10.1002/jbio.201300125. Epub 2013 Oct 15.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FWH20190105H
Identifier Type: -
Identifier Source: org_study_id